Research programme: CNS therapeutics - Jagiellonian University/Neurolixis
Latest Information Update: 13 Jan 2015
At a glance
- Originator Jagiellonian University; Neurolixis
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Major depressive disorder; Schizophrenia
Most Recent Events
- 09 Jan 2015 Early research in Major depressive disorder and Schizophrenia in USA and Poland (unspecified route)